Peng Lu sold $427k of PHVS
Chief Medical Officer at Pharvaris N.V.. 14,166 shares at an average of $30.17, traded May 1, 2026, filed May 5, 2026.
Score components
- +15RoleOfficer
- +17Trade size$427k at market
- +5Share of holdings soldSold 18% of holdings
- +15Cluster6 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001193125-26-206273, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| May 1, 2026 | MOption exercise Common Stock10b5-1 | +14,166 | $2.59 | $37k | 80,249 | May 5, 2026 |
| May 1, 2026 | SOpen-market sale Common Stock10b5-1 | -14,023 | $30.16 | $423k | 66,226 | May 5, 2026 |
| May 1, 2026 | SOpen-market sale Common Stock10b5-1 | -143 | $31.00 | $4,433 | 66,083 | May 5, 2026 |
| May 1, 2026 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -14,023 | $0.00 | $0 | 205,451 | May 5, 2026 |
| May 1, 2026 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -143 | $0.00 | $0 | 205,308 | May 5, 2026 |
Related signals
Other insiders at Pharvaris N.V. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 51Moderate | Pharvaris N.V. | Viviane Monges director | $396k 11,969 shares | -69% | |
| 20Weak | Pharvaris N.V. | Johannes Gerardus Christiaan Petrus Schikan director | $29k 800 shares | -1% | |
| 49Moderate | Pharvaris N.V. | David W. Nassif CFO / CLO | $219k 6,000 shares | -5% | |
| 60Notable | Pharvaris N.V. | Elisabeth Bjork director | $2.0M 52,500 shares | -78% | |
| 34Weak | Pharvaris N.V. | Robert Glassman director | $559k 14,493 shares | -58% | |
| 57Moderate | Pharvaris N.V. | Anne Lesage Chief Early Development | $765k 20,000 shares | -21% | |
| 65Notable | Pharvaris N.V. | Peng Lu President | $3.5M 100,000 shares | -61% | |
| 75Notable | Pharvaris N.V. | Johannes Gerardus Christiaan Petrus Schikan director | $7.0M 200,000 shares | -63% | |
| 60Notable | Pharvaris N.V. | Stefan Andreas Abele Chief Technical Ops Officer | $1.8M 46,400 shares | -54% | |
| 20Weak | Pharvaris N.V. | Robert Glassman director | $332k 8,667 shares | -45% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.